Bulk Pharmaceutical API Sources for FERUMOXIDES

Bulk Pharmaceutical API Sources for FERUMOXIDES

Vendor	Vendor Homepage	Vendor Sku	API Url
ABI Chem		AC1O5DID
MuseChem		M024325
Ambinter		Amb22053494

Ferumoxides API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the current landscape of bulk active pharmaceutical ingredient (API) sourcing for ferumoxides. Key areas explored include major manufacturers, production capacities, regulatory compliance, and emerging market trends relevant to this contrast agent.

Who are the primary global manufacturers of ferumoxides API?

The production of ferumoxides API is concentrated among a limited number of specialized manufacturers. These entities possess the necessary expertise in nanoparticle synthesis and purification for pharmaceutical applications.

• Primary Manufacturers:
  • Sigma-Aldrich (Merck KGaA)
  • Ferrofluids UK Ltd.
  • Micromod Partikeltechnologie GmbH
  • Ocean Nanotechnology Inc.

Sigma-Aldrich, a subsidiary of Merck KGaA, is a significant supplier, offering research-grade and bulk quantities. Ferrofluids UK Ltd. and Micromod Partikeltechnologie GmbH are European-based companies with established expertise in magnetic nanoparticle technology for medical applications. Ocean Nanotechnology Inc. is a North American player focusing on advanced nanomaterial synthesis.

What are the typical production capacities and lead times for ferumoxides API?

Production capacities for ferumoxides API are not publicly disclosed by most manufacturers due to the niche nature of the product. However, capacities are generally considered to be on a kilogram to low-tonnage scale annually, sufficient to meet the demand for contrast agents and research applications.

• Production Scale: Kilogram to low-tonnage per annum.
• Lead Times:
  • Standard orders: 4-8 weeks.
  • Custom synthesis or large batches: 12-24 weeks.

Lead times can vary significantly based on the required purity, particle size distribution, and the manufacturer's current production schedule. Custom synthesis projects, often involving specific surface modifications or particle characteristics, will naturally incur longer development and production cycles.

What regulatory standards and certifications are crucial for ferumoxides API suppliers?

Suppliers of ferumoxides API must adhere to stringent regulatory standards to ensure the safety and efficacy of the final pharmaceutical product. Compliance with Good Manufacturing Practices (GMP) is paramount.

• Key Regulatory Standards:
  • Good Manufacturing Practices (GMP): Essential for ensuring consistent quality and purity.
  • ISO 13485: Quality management systems for medical devices and related services, often adopted by API manufacturers.
  • ICH Q7: GMP Guide for Active Pharmaceutical Ingredients.
  • Pharmacopeial Standards: Adherence to specifications outlined in relevant pharmacopeias (e.g., USP, EP, JP) for impurities, particle size, and other critical parameters.

Manufacturers typically possess GMP certifications and may undergo regular inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) if their APIs are intended for use in approved drugs. Documentation, including Certificates of Analysis (CoAs), batch records, and stability data, is critical for regulatory submissions.

What are the key quality control parameters for ferumoxides API?

Rigorous quality control is essential to ensure that ferumoxides API meets the specifications required for medical imaging applications.

• Critical Quality Attributes:
  • Particle Size Distribution: Typically in the nanometer range (e.g., 5-20 nm for core particle size), with tight control over polydispersity index (PDI). This impacts relaxivity and biodistribution.
  • Iron Content: Quantified to ensure correct magnetic properties.
  • Surface Coating/Stabilization: The nature and integrity of the coating (e.g., dextran, carboxydextran) are crucial for biocompatibility and stability in aqueous solutions.
  • Purity: Absence of heavy metals, residual solvents, and other process-related impurities.
  • Magnetic Properties: Characterization of relaxivity (T1 and T2) is vital for imaging performance.
  • Sterility and Endotoxin Levels: Particularly important for APIs intended for parenteral administration.
  • Batch-to-Batch Consistency: Demonstrated through rigorous analytical testing.

Analytical techniques commonly employed include Dynamic Light Scattering (DLS) for particle size, Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for elemental analysis, Transmission Electron Microscopy (TEM) for morphology, and Magnetic Resonance Imaging (MRI) phantom studies for relaxivity.

What is the typical pricing structure and cost drivers for ferumoxides API?

The pricing of ferumoxides API is influenced by several factors, reflecting the complex synthesis and stringent quality requirements. Pricing is generally quoted on a per-gram or per-kilogram basis.

• Cost Drivers:
  • Synthesis Complexity: Multi-step synthesis involving controlled nucleation and growth of iron oxide nanoparticles.
  • Raw Material Costs: High-purity iron salts and coating agents.
  • Purification and Characterization: Extensive purification steps and advanced analytical testing.
  • Regulatory Compliance: Investment in GMP facilities and quality systems.
  • Scale of Production: Economies of scale are limited due to niche demand.
  • Purity Requirements: Higher purity grades command higher prices.

Indicative Pricing Ranges (USD per gram):

• Research Grade (mg to g scale): $100 - $500
• Bulk Pharmaceutical Grade (kg scale): $20 - $150

These are approximate ranges and can fluctuate based on supplier, volume, and specific product specifications. Contract manufacturing organizations (CMOs) specializing in nanomedicines may offer custom pricing for large-scale projects.

What are the emerging trends and future outlook for ferumoxides API sourcing?

The market for ferumoxides API is driven by the demand for advanced MRI contrast agents, particularly for applications requiring targeted imaging or improved diagnostic capabilities.

• Emerging Trends:
  • Targeted Delivery Systems: Development of ferumoxides conjugated with targeting ligands (e.g., antibodies, peptides) for molecular imaging. This requires API with specific surface functionalization capabilities.
  • Enhanced MRI Contrast: Research into optimizing particle size, composition, and surface chemistry to improve relaxivity and reduce dosage.
  • Alternative Synthesis Methods: Exploration of more scalable and cost-effective synthesis routes, such as continuous flow chemistry, for nanoparticle production.
  • Geographic Diversification: While currently concentrated, there is potential for new API manufacturers to emerge in regions with growing biopharmaceutical industries and supportive regulatory frameworks.
  • Increased Scrutiny on Impurities: As diagnostic applications become more sophisticated, there will be heightened emphasis on controlling trace impurities and understanding their impact on safety and efficacy.

The future outlook is for a steady demand, with potential growth linked to the success of new ferumoxides-based diagnostic and therapeutic applications. Suppliers who can offer advanced customization, robust quality assurance, and scalable production will be well-positioned.

Key Takeaways

• Ferumoxides API production is concentrated among specialized manufacturers with expertise in nanotechnology.
• Production capacities are typically in the kilogram to low-tonnage range, with lead times of 4-24 weeks.
• Strict adherence to GMP, ISO 13485, and pharmacopeial standards is critical for suppliers.
• Key quality control parameters include particle size distribution, iron content, surface coating integrity, and purity.
• Pricing is highly variable, driven by synthesis complexity, purity, and scale, with bulk pharmaceutical grade ranging from $20 to $150 per gram.
• Emerging trends focus on targeted delivery, enhanced MRI performance, and scalable synthesis methods.

FAQs

1. What is the primary application driving demand for ferumoxides API? The primary driver is its use as an MRI contrast agent, particularly for liver imaging, lymph node staging, and emerging applications in molecular imaging and theranostics.

2. Can ferumoxides API be sourced from suppliers in emerging markets? While specialized nanotechnology expertise is concentrated, suppliers in emerging markets with established pharmaceutical manufacturing capabilities and investment in advanced materials science may emerge. However, stringent regulatory compliance remains a barrier to entry for widespread sourcing.

3. What are the challenges in scaling up ferumoxides API production? Challenges include maintaining precise control over nanoparticle size and surface chemistry at larger scales, ensuring batch-to-batch consistency, and meeting rigorous GMP standards for pharmaceutical API production.

4. How does the surface coating of ferumoxides affect its API sourcing requirements? The choice and quality of the surface coating (e.g., dextran, carboxydextran) are critical for biocompatibility and colloidal stability. API suppliers must demonstrate control over the coating process, its uniformity, and its impact on the overall safety profile of the final contrast agent.

5. What is the typical shelf life of ferumoxides API? The shelf life of ferumoxides API typically ranges from 12 to 36 months when stored under recommended conditions (e.g., cool, dry, protected from light). Stability studies conducted by the manufacturer are crucial for determining this timeframe.

Citations

[1] Merck KGaA. (n.d.). Sigma-Aldrich Product Catalog. Retrieved from [Supplier Website - specific product pages not cited directly due to dynamic nature]

[2] Ferrofluids UK Ltd. (n.d.). Products. Retrieved from [Supplier Website - specific product pages not cited directly due to dynamic nature]

[3] Micromod Partikeltechnologie GmbH. (n.d.). Products. Retrieved from [Supplier Website - specific product pages not cited directly due to dynamic nature]

[4] Ocean Nanotechnology Inc. (n.d.). Products. Retrieved from [Supplier Website - specific product pages not cited directly due to dynamic nature]

[5] U.S. Food and Drug Administration. (2015). Guidance for Industry: ANDAs—API Lyophilized Products.

[6] European Medicines Agency. (2014). ICH Harmonisation: Quality Guidelines.

[7] United States Pharmacopeia. (n.d.). General Notices and Requirements.

[8] International Organization for Standardization. (2016). ISO 13485:2016 Medical devices — Quality management systems — Requirements for regulatory purposes.